Based on company history and the stock chart since inception, I would say disaster. But the company does appear to have a treatment close to gaining marketing approval (for ATC) and a potential blockbuster treatment just getting started with testing (OXi4503 for Acute Myelogenous Leukemia). So this is your typical boom or bust, news-driven stock. I wouldn't bet the house, but it could be exciting (and frustrating) to watch over the next few years.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.